Workflow
New Toll Brothers Luxury Townhome Community, Stonemill Village, is Now Open in Downingtown, Pennsylvania
GlobeNewswire· 2025-04-23 21:43
DOWNINGTOWN, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced its newest Chester County townhome community, Stonemill Village, is now open for sale. The Toll Brothers Sales Center and model home are open for tours at 5 Grayson Lane in Downingtown, Pennsylvania. Located in the prestigious Downingtown Area School District, Stonemill Village will feature 89 two-story townhomes in a quiet neighborhood close to every convenience ...
Beaver Hollow Wellness Responds to Servotronics' Escalating Proxy Tactics
Prnewswire· 2025-04-23 21:40
Calls for Accountability and Shareholder-Centered ReformBUFFALO, N.Y., April 23, 2025 /PRNewswire/ -- Beaver Hollow Wellness, LLC ("BHW"), the largest active shareholder of Servotronics, Inc. (NASDAQ: SVT), today issued the following statement in response to the Company's amended proxy statement filed April 22, 2025:"Servotronics' latest filing is a clear sign of a board under pressure and out of touch," said Paul L. Snyder III, Chairman of BHW. "The escalation in rhetoric, along with newly inserted languag ...
LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell)
Prnewswire· 2025-04-23 21:35
Revolutionizing Vaccination Safety with Needle-Free Reconstitution TechnologyBEIJING, April 23, 2025 /PRNewswire/ -- On April 18, 2025, LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company") successfully held the 2025 CSO ("Contract Sales Organization") Annual Meeting and the launch meeting of YSJA™ rabies vaccine (Vero cell) novel packaging solution (liquid drug transfer device) in Changsha, Hunan Province. Approved for lot release by regulatory authorities on April 15, 2025, ...
Fortinet Achieves GovRAMP Security Authorization
Newsfilter· 2025-04-23 21:31
SUNNYVALE, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- News Summary Fortinet®, the global cybersecurity leader driving the convergence of networking and security, today announced that FortiGuard AI-Powered Security Services and FortiCare Services have received GovRAMP, previously known as StateRAMP, authorization at a moderate impact level from the Government Risk and Authorization Management Program (GovRAMP®). "Fortinet's GovRAMP authorization underscores our commitment to delivering trusted security so ...
Premium Global Income Split Corp. Announces Successful Overnight Offering of Preferred Shares and Class A Shares
GlobeNewswire· 2025-04-23 21:31
Not for distribution to U.S. newswire services or for dissemination in the United States. TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- (TSX: PGIC.PR.A; PGIC) – Premium Global Income Split Corp. (the “Fund”) is pleased to announce a successful overnight treasury offering of 2,100,000 Preferred Shares and 2,100,000 Class A Shares for gross proceeds of approximately $35,175,000. The Preferred Shares and Class A Shares will continue to trade on the Toronto Stock Exchange (the “TSX”) under the existing symbols PG ...
Correction: Form 8.3 - [Advanced Medical Solutions Group]
GlobeNewswire· 2025-04-23 21:31
8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose re ...
Consolidated and audited report of AS Pro Kapital Grupp for the financial year 2024 will not be completed on time
GlobeNewswire· 2025-04-23 21:30
Consolidated and audited report of AS Pro Kapital Grupp for the financial year 2024 will not be completed on time In the financial calendar for 2025, published on 15 November 2024, AS Pro Kapital Grupp announced that consolidated audited financial statements for the financial year 2024 will be published on 25 April 2025 at the latest. Due to the delay in auditing financial statement of one of the subsidiaries for the financial year 2024, the audit of AS Pro Kapital Grupp consolidated financial statements f ...
Morris State Bancshares Announces Quarterly Earnings and Declares Second Quarter Dividend
GlobeNewswire· 2025-04-23 21:22
DUBLIN, Ga., April 23, 2025 (GLOBE NEWSWIRE) -- Morris State Bancshares, Inc. (OTCQX: MBLU) (the “Company”), the parent of Morris Bank, today announced net income of $4.9 million for the quarter ending March 31, 2025, representing an increase of $22 thousand, or 0.45%, compared to net income of $4.9 million for the quarter ended March 31, 2024. In the linked quarter comparison, net income decreased $1.2 million, or 20.04%, compared to net income of $6.1 million for the quarter ending December 31, 2024. Net ...
Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities
Newsfilter· 2025-04-23 21:20
文章核心观点 - 临床阶段生物技术公司Silexion Therapeutics与先进交付技术和临床制造解决方案全球领导者Catalent达成战略合作,推进SIL204开发项目,有望在2026年上半年启动人体临床试验 [1][4] 合作内容 - Catalent将在法国利摩日的先进设施为Silexion的下一代siRNA候选药物SIL204进行配方开发和临床制造活动,专注优化其全身和肿瘤内递送配方,支持双路线开发策略 [2] 合作基础 - Silexion近期报告的临床前数据显示SIL204在减少原位胰腺癌模型的原发肿瘤生长和转移扩散方面有显著疗效,且可靶向多种KRAS突变 [3] 合作意义 - 此次合作是SIL204开发计划的重大进展,Catalent在复杂配方开发方面的专业知识将有助于优化SIL204配方,提升其治疗潜力 [4] 公司后续计划 - 公司计划在2025年进行额外的毒理学和药效学研究,2025年下半年向以色列卫生部提交潜在监管申请,2026年上半年向欧盟提交申请 [5] 公司简介 - Silexion Therapeutics是专注肿瘤学的临床阶段生物技术公司,开发创新RNA干扰疗法治疗KRAS突变驱动的实体瘤,其第一代产品LODER™在不可切除胰腺癌2期试验中结果良好,SIL204在临床前研究中显示出显著潜力 [6]
Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities
GlobeNewswire· 2025-04-23 21:20
文章核心观点 - 临床阶段生物技术公司Silexion Therapeutics宣布与Catalent达成战略合作,推进下一代siRNA候选药物SIL204的开发,有望在2026年上半年启动人体临床试验 [1][4] 合作内容 - Catalent将在法国利摩日的先进设施为Silexion的SIL204进行配方开发和临床制造活动,专注优化其全身和瘤内递送配方,支持双路线开发策略 [2] 合作基础 - Silexion近期报告的临床前数据显示SIL204在减少原位胰腺癌模型的原发肿瘤生长和转移扩散方面有显著疗效,可靶向多种KRAS突变 [3] 合作意义 - 此次合作是SIL204开发计划的重大进展,Catalent在复杂配方开发方面的专业知识将有助于优化SIL204的配方,提升其治疗潜力 [4] 后续计划 - Silexion计划在2025年进行额外的毒理学和药效学研究,2025年下半年向以色列卫生部提交潜在监管申请,2026年上半年向欧盟提交申请 [5] 公司介绍 - Silexion是专注肿瘤学的临床阶段生物技术公司,开发创新RNA干扰疗法治疗KRAS突变驱动的实体瘤,第一代产品LODER在二期试验中显示出前景,SIL204在临床前研究中潜力显著 [6]